April 2012 KonLin Letter Cites Cutting-Edge Technology For Stem Cells And Treatments For Cancer And Diabetes, And Reaffirms Buy Recommendation

Nuvilex, Inc. (OTCQB: NVLX) reports Konrad Kuhn has included Nuvilex in his most recent KonLin Letter with a Buy recommendation, citing the company’s unique cell encapsulation technology for use with stem cells and treatment of pancreatic cancer and diabetes. He set the first target price at $0.50-0.60 and reconfirmed his target of $1-2.

“The KonLin Letter” is considered an authority on low-priced stocks, has consistently been one of the leading publications on Wall Street, and is rated one of the best performing market letters in the nation. Therefore, we were excited to learn of our inclusion in his private subscription-based letter. The April 2012 KonLin Letter stated, “NVLX represents one of the most remarkable investments in health care in decades.”

The KonLin Letter specializes in stocks under $10, with emphasis on emerging growth and special situations poised for explosive price appreciation. Konrad Kuhn's economic forecasts have been extremely accurate for over three decades. That stellar record puts him among the very few market analysts who successfully predicted: the 1987 market crash/correction, the 1998 "selling climax" and the 2000 NASDAQ crash, the bear markets of 2001 and 2002, the ongoing 7-year secular bull market in small- and micro-cap stocks, and the "07-08" financial meltdown.

As a result of his analysis, Mr. Kuhn commented, “Most companies only have expertise in one treatment category. By buying NVLX, investors have an opportunity to buy stock in what will likely become one of the leading companies treating cancer, diabetes, and stem cell utilization. Since the NVLX delivery system can be used in so many therapies, the market opportunity is in the tens of billions, and leading drug companies will likely partner or license technology from NVLX to improve their own drugs and maintain their market shares.”

In justifying the 1 st target price, KonLin stated, “Leading pharmaceutical firms in each treatment segment could seek development and marketing partnerships with NVLX worth $50–100 mil. in order to gain access to the revolutionary NVLX cell technology for converting their best-selling drugs. Once the SG Austria deal is closed, investors should expect a flurry of development activity which will serve as the catalyst for a steady rise in the stock on its way to our 1st target of .50-.60.”

About Nuvilex

Nuvilex, Inc. (OTCQB: NVLX) is an emerging international biotechnology provider of live therapeutically valuable, encapsulated cells and services for research and medicine. Substantial effort of our corporate activities, alone and in concert with SG Austria, are near completion, ultimately driving our strong future together. Our company’s clinical offerings will include cancer, diabetes and other treatments using the company’s industry-leading cell and gene therapy expertise and cutting-edge, live-cell encapsulation technology.

Safe Harbor Statement

This press release contains forward-looking statements described within the Private Securities Litigation Reform Act of 1995 involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.

Copyright Business Wire 2010